445 A PHASE 2B TRIAL COMPARING 24 TO 48 WEEKS TREATMENT WITH TEGOBUVIR (GS-9190)/PEG/RBV TO 48 WEEKS TREATMENT WITH PEG/RBV FOR CHRONIC GENOTYPE 1 HCV INFECTION

Autor:	Michael B. Bennett, John G. McHutchison, E. Godofsky, David W. Oldach, Graham R. Foster, J. Hinkle, M. Ryan, James T. Simpson, Ira M. Jacobson, Eric Lawitz, Robert Flisiak
Rok vydání:	2011
Předmět:	medicine.medical_specialty Hepatology business.industry Internal medicine PEG ratio Genotype medicine business Gastroenterology
Zdroj:	Journal of Hepatology. 54:S181
ISSN:	0168-8278
DOI:	10.1016/s0168-8278(11)60447-9
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::6f2a310d84aeb5b2db78fb0b44ddc8df https://doi.org/10.1016/s0168-8278(11)60447-9 Zobrazit plný text záznamu Full Text from ScienceDirect